How Long Is a Mycoplasma Infection Contagious?

Most people infected with Mycoplasma pneumoniae shed the bacterium for several weeks, with the majority testing negative by about one month after symptoms appear. But a meaningful minority continue to harbor and potentially spread the organism for much longer, up to four months in some studies. The contagious window is harder to pin down than it might sound, partly because a person can start spreading the infection well before feeling sick, and partly because antibiotics do not always shut off shedding the way most people assume.

Contagious Before You Feel Sick

One of the trickier aspects of Mycoplasma pneumoniae is its long incubation period. A classic family-transmission study found a median incubation period of about 23 days, meaning roughly three weeks can pass between exposure and the appearance of symptoms.¹ During at least part of that window, the bacterium is already multiplying in the upper respiratory tract and can be passed to others through close contact.

Mathematical modeling of M. pneumoniae outbreaks has reinforced just how significant this pre-symptomatic transmission is. One analysis found that transmission from people who are in the latent stage, before they develop a cough or fever, actually contributes more to the spread of the disease than transmission from people who are visibly sick.² That finding challenges the intuition that you are mainly a risk to others when you are coughing and sneezing. In reality, because the incubation period is so long and people continue their normal routines during it, the pre-symptomatic phase is a major driver of outbreaks in households and schools.

Shedding Duration After Symptoms Appear

Once symptoms start, how long does shedding continue? The best evidence comes from studies that followed patients with repeat testing over time. A large observational study of children found that the majority, roughly three-quarters of both symptomatic and asymptomatic children carrying M. pneumoniae, tested negative after one month.³ But the remaining quarter continued to carry the organism, with some still testing positive at four months.

Older family studies tell a similar story. In a study of 36 families where the index case had confirmed M. pneumoniae pneumonia, the carrier state frequently lasted one to three months, even in patients who received antibiotic treatment.¹ Some individual case reports push the timeline even further. One diagnostic study documented PCR-positive throat swabs in a patient at 46 days after the onset of symptoms, suggesting viable organisms were still present in the upper airway well over six weeks into the illness.⁴

So a reasonable summary is this: most people stop shedding within about four weeks after their symptoms begin, but a substantial fraction remain positive for two to four months. Whether ongoing PCR positivity past the acute illness represents truly infectious organisms or just residual DNA fragments is debated, but the conservative assumption from a public-health standpoint is that positive detection means possible contagiousness.

Asymptomatic Carriers Complicate the Picture

A person does not have to feel sick to be carrying M. pneumoniae in their throat and nose. Studies of healthy children without any respiratory symptoms have found surprisingly high carriage rates. In one comparison of over 400 asymptomatic children and about 300 symptomatic children, M. pneumoniae DNA was detected in roughly 21% of the healthy group versus 16% of the sick group, and the difference was not statistically significant.⁵ Neither quantitative PCR, serology, nor culture could reliably tell the difference between an asymptomatic carrier and someone actively infected.

This matters for the contagiousness question in a practical way. If a large percentage of healthy children are silently carrying the bacterium, then isolating only the obviously sick person in a household or classroom may do little to stop transmission. A review of the pediatric literature concluded that high rates of carriage in healthy children make it essentially impossible for current diagnostic tools to distinguish harmless carriage from genuine infection.⁶ The practical implication is that in a household where one person is diagnosed, other family members may already be colonized and capable of passing the organism along, whether or not they develop symptoms themselves.

How It Spreads and Why Close Contact Matters

Mycoplasma pneumoniae is transmitted through respiratory droplets, the kind produced by coughing, sneezing, and close conversation. Unlike certain hardier pathogens, mycoplasmas are fragile. They lack a cell wall, which makes them unusually susceptible to drying out. That vulnerability to desiccation is the main reason M. pneumoniae requires relatively close, prolonged contact to spread.⁷ It does not survive well on surfaces or travel long distances through the air the way, say, measles virus does.

This biology explains why outbreaks tend to cluster in settings where people spend extended time in close quarters: families, dormitories, military barracks, and schools. In one well-documented school-based outbreak, just 10% of households accounted for more than 60% of all physician visits for pneumonia or cough. Among household contacts of students who had pneumonia, about 42% went on to develop pneumonia themselves and another 32% sought care for persistent cough.⁸ Those are remarkably high household attack rates and illustrate how efficiently the organism spreads once it gets into a family, even though it requires close contact to do so.

Children as the Primary Reservoir

Most Mycoplasma pneumoniae infections occur in school-age children and young adults, and children appear to play a disproportionate role in maintaining transmission. In family studies, children were infected at much higher rates than adults when one family member brought the infection home: about 84% of children in affected households became infected compared with 41% of adults.¹

Children also appear to remain contagious for longer. A comprehensive review noted that transmission rates among families suggest children can maintain contagiousness over a long period, ranging from months to what some authors describe as years in certain populations.⁹ Adults, by contrast, tend to experience milder “walking pneumonia” symptoms and presumably shed the organism for a shorter time, though formal head-to-head comparisons are limited. The upshot for families is that when a child is diagnosed, the window during which that child could be transmitting the infection to siblings, parents, and classmates is probably longer than most people expect, and keeping the child home for the first few days of illness alone is unlikely to fully contain spread.

Why Antibiotics Do Not Always End Contagiousness

A common assumption is that once someone starts antibiotics, the contagious period is effectively over within a day or two. For M. pneumoniae, the reality is messier. Even in the era before macrolide resistance was a widespread concern, the classic family study from the 1960s noted that treatment with tetracycline “seemed neither to cure the symptoms completely nor to abolish the carrier state that often lasted one to three months.”¹ In other words, antibiotic therapy could shorten symptoms and reduce their severity, but it did not reliably clear the organism from the throat.

The situation has gotten worse with the rise of macrolide-resistant strains. Macrolides like azithromycin are the first-line treatment for Mycoplasma pneumoniae in most countries, but resistance has been climbing. One large pediatric study reported an average macrolide-resistance rate of about 24%, and patients infected with resistant strains had significantly longer fevers, longer hospital stays, and more complications like lung consolidation.¹⁰ When the standard antibiotic is not working, the illness drags on and so does the opportunity for the person to spread the infection to others.

A study of hospitalized children in Ohio found a stark contrast between macrolide-sensitive and macrolide-resistant infections: children with sensitive strains had a median hospital stay of 2 days, while those with resistant strains stayed a median of 8 days.¹¹ The prolonged illness in the resistant group was largely because the infections went unidentified for days while patients received antibiotics that were not working, allowing symptoms (and presumably shedding) to continue unchecked. Broader reviews confirm this pattern: fever duration, cough duration, and the length of antibiotic courses are all significantly longer in macrolide-resistant infections.¹²

None of this means antibiotics are useless. For macrolide-sensitive infections, treatment clearly helps patients feel better faster and probably shortens the contagious window. But “probably” is doing real work in that sentence. There is no firm evidence that a person on appropriate antibiotics becomes non-contagious within 24 to 48 hours the way you might expect with, say, strep throat after starting penicillin. If you are looking for a safe rule of thumb, treat the person as potentially contagious for at least several days after starting effective therapy, and keep in mind that household members may already be colonized regardless.

Practical Guidance for Households and Schools

Because M. pneumoniae requires close, sustained contact to spread and does not survive long outside the body, the most effective precautions are the ones that reduce droplet exposure within shared living spaces. Good hand hygiene, covering coughs, and avoiding the sharing of utensils and drinking cups are all worthwhile. Ventilating indoor spaces helps too, since diluting the concentration of respiratory droplets in the air reduces the chance of transmission.

There is no standard “isolation period” for M. pneumoniae the way there is for chickenpox or measles. Most guidelines focus on symptom management and antibiotic therapy rather than strict exclusion timelines. That said, the evidence reviewed above suggests that keeping a symptomatic person home during the acute febrile phase, typically the first week or so, is reasonable. The challenge is that by the time someone is diagnosed, they have likely been contagious for weeks during the incubation period, and asymptomatic household contacts may already be carrying the organism.

For schools dealing with an outbreak, the clustering pattern described in the Ohio school investigation illustrates that a small number of households can drive a large share of cases.⁸ Notifying families and encouraging evaluation of children with prolonged cough is more productive than attempting mass exclusions, which are impractical given that so many carriers are asymptomatic.

Mycoplasma Genitalium Has a Different Timeline

When people ask about “mycoplasma infections,” they often mean M. pneumoniae, the respiratory pathogen. But Mycoplasma genitalium is a sexually transmitted species that causes urethritis and cervicitis, and its contagious window follows entirely different rules. Rather than weeks, M. genitalium infections can persist for months without treatment. A cohort study of women found that about 55% had spontaneously cleared the infection within three months, roughly 83% within six months, and 93% within a year.¹³ That means a person who is not tested or treated could be infectious for half a year or more.

Immune status also affects how long M. genitalium sticks around. In the same study, women with HIV cleared the infection significantly more slowly, and those with lower immune-cell counts cleared it slower still. Adding to the challenge, about 39% of women who cleared the infection went on to become reinfected, likely through re-exposure to untreated partners.¹³ So for the genital species, the contagious period is open-ended until effective treatment is given and a test-of-cure confirms clearance, a very different picture from the respiratory pathogen that most people are asking about.

Why Reinfection Happens

Unlike some infections that leave you with lasting immunity, M. pneumoniae does not consistently produce durable protection. The immune response to the bacterium is real but often incomplete, and reinfections have been documented in both children and adults. Partly this is because the bacterium’s surface proteins can vary, and partly it is because the immune memory from a mild upper-respiratory infection does not always translate into protection against a later, more significant exposure.

Reinfection risk is relevant to the contagiousness question because it means that previous exposure does not take people out of the susceptible pool. In a household where M. pneumoniae circulates, even family members who were infected during a prior wave can be reinfected and start shedding again, extending the total period during which the household poses a transmission risk to visitors and close contacts. This cycling of infection within families is one reason that some reviews describe contagiousness in children as potentially lasting months to years.⁹ The “years” figure is less about a single continuous infection and more about repeated rounds of carriage and reinfection within a household or school community that keeps the organism in circulation.

The Limits of Testing

One frustration for anyone trying to determine whether they are still contagious is that the available tests are imperfect. PCR, the most sensitive method for detecting M. pneumoniae, can pick up residual bacterial DNA in the throat for weeks after the organism is no longer viable. A positive PCR result at six weeks does not necessarily mean the person is still capable of infecting others, it may just mean fragments are still being cleared. Serology, on the other hand, measures the immune response and tells you that an infection occurred at some point, but says nothing about whether the person is currently shedding live organisms.

The core diagnostic problem was summed up in a review noting that neither serology, quantitative PCR, nor culture can reliably distinguish asymptomatic carriage from active infection in children.⁵ Culture, which would definitively show whether live organisms are present, is slow and technically difficult for mycoplasmas, so it is rarely used in routine clinical practice. This means there is no easy “test of clearance” for M. pneumoniae the way there is for some other infections. In practice, clinicians rely on symptom resolution and the passage of time rather than repeat testing to judge when someone is no longer a risk.

For M. genitalium, by contrast, nucleic acid amplification tests are now standard in many settings, and guidelines increasingly recommend a test-of-cure several weeks after treatment to confirm clearance, precisely because untreated or inadequately treated infections can linger for months and silently spread to sexual partners.

1
JAMA. Epidemiology of Mycoplasma pneumoniae Infection in Families
2
World Scientific (Journal of Biological Systems). LATENT INFECTIVITY AND REFINED EQUILIBRIUM CONDITIONS IN MYCOPLASMA PNEUMONIAE TRANSMISSION DYNAMICS
3
PLOS Medicine. Carriage of Mycoplasma pneumoniae in the Upper Respiratory Tract of Symptomatic and Asymptomatic Children: An Observational Study
4
PubMed Central. Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection
5
Breathe. Mycoplasma pneumoniae respiratory tract infections in children: when and how to diagnose and treat
6
PubMed Central. Infection with and Carriage of Mycoplasma pneumoniae in Children
7
FEMS Microbiology Reviews. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections
8
PubMed. Community outbreak of Mycoplasma pneumoniae infection: school-based cluster of neurologic disease associated with household transmission of respiratory illness
9
Frontiers in Microbiology. A Compendium for Mycoplasma pneumoniae
10
PubMed. Mycoplasma pneumoniae in pediatric patients: Do macrolide-resistance and/or delayed treatment matter?
11
Emerging Infectious Diseases. Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA
12
Frontiers in Microbiology. Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment
13
PubMed Central. Natural history of Mycoplasma genitalium Infection in a Cohort of Female Sex Workers in Kampala, Uganda